DGIdb - DENOSUMAB Drug Record

DENOSUMAB chembl:CHEMBL1237023 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PROLIA
DENOSUMAB
AMG-162
TK-006
PROLIA, XGEVA
TK006
PROLIA, RANMARK XGEVA
XGEVA
drugbank:06643
chemidplus:615258-40-7
chembl:CHEMBL1237023
rxcui:993449

Drug Info:

FDA Approval	Giant cell tumor of the bone
Drug Class	Therapeutic Antibodies
FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antiosteoporotic agent
Year of Approval	2010
Drug Class	osteoporosis prophylaxis

(5 More Sources)

Publications:

Lipton et al., 2008, RANKL inhibition in the treatment of bone metastases., Curr Opin Support Palliat Care
Westenfeld et al., 2006, Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density., Nephrol. Dial. Transplant.
Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.

DENOSUMAB TNFSF11

Interaction Score: 69.56

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Denosumab

Novel drug target Established target

PMIDs:
18685421 16702197

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND TTD
DENOSUMAB BRCA1

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Emerging

Approval Status Clinical Study

Response Type not applicable

PMIDs:
27322743

Sources:
JAX-CKB

MyCancerGenome: DENOSUMAB
- Version: 20-Jun-2017
Alternate Names:

XGEVA Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Giant cell tumor of the bone

Publications:
TEND: DENOSUMAB
- Version: 01-August-2011
Alternate Names:

DENOSUMAB Primary Drug Name

Drug Info:

Drug Class osteoporosis prophylaxis

Year of Approval 2010

Publications:
TdgClinicalTrial: DENOSUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiosteoporotic agent

Drug Class monoclonal antibody

FDA Approval approved

Publications:
JAX-CKB: Denosumab
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.
TTD: Denosumab
- Version: 2020.06.01
Alternate Names:

D08WSY TTD Drug ID

Drug Info:

Publications:
TALC: DENOSUMAB
- Version: 12-May-2016
Alternate Names:

DENOSUMAB Primary Drug Name

DENOSUMAB Drug Generic Name

XGEVA Drug Trade Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1237023
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1237023
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: DENOSUMAB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Evidence Type	Emerging
Approval Status	Clinical Study
Response Type	not applicable

DENOSUMAB	Primary Drug Name
DENOSUMAB	Drug Generic Name
XGEVA	Drug Trade Name

antibody (inhibitory)
inhibitor (inhibitory)

Notes
Trial Name	Denosumab
Novel drug target	Established target

DENOSUMAB Drug Record

DENOSUMAB chembl:CHEMBL1237023 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

DENOSUMAB TNFSF11

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Trial Name Denosumab Novel drug target Established target

PMIDs: 18685421 16702197

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND TTD

DENOSUMAB BRCA1

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Emerging Approval Status Clinical Study Response Type not applicable

PMIDs: 27322743

Sources: JAX-CKB

MyCancerGenome: DENOSUMAB

Alternate Names: XGEVA Trade Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval Giant cell tumor of the bone

Publications:

TEND: DENOSUMAB

Alternate Names: DENOSUMAB Primary Drug Name

Drug Info: Drug Class osteoporosis prophylaxis Year of Approval 2010

Publications:

TdgClinicalTrial: DENOSUMAB

Alternate Names:

Drug Info: Drug Indications antiosteoporotic agent Drug Class monoclonal antibody FDA Approval approved

Publications:

JAX-CKB: Denosumab

Alternate Names:

Drug Info:

Publications: Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.

TTD: Denosumab

Alternate Names: D08WSY TTD Drug ID

Drug Info:

Publications:

TALC: DENOSUMAB

Alternate Names: DENOSUMAB Primary Drug Name DENOSUMAB Drug Generic Name XGEVA Drug Trade Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1237023

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1237023

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: DENOSUMAB

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Denosumab

Novel drug target Established target

PMIDs:
18685421 16702197

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Emerging

Approval Status Clinical Study

Response Type not applicable

PMIDs:
27322743

Sources:
JAX-CKB

Alternate Names:

XGEVA Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Giant cell tumor of the bone

Alternate Names:

DENOSUMAB Primary Drug Name

Drug Info:

Drug Class osteoporosis prophylaxis

Year of Approval 2010

Drug Info:

Drug Indications antiosteoporotic agent

Drug Class monoclonal antibody

FDA Approval approved

Publications:

Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.

Alternate Names:

D08WSY TTD Drug ID

Alternate Names:

DENOSUMAB Primary Drug Name

DENOSUMAB Drug Generic Name

XGEVA Drug Trade Name